RGEN.US Repligen Corporation

Healthcare Life Sciences Tools & Services USA Stocks
162.18 USD
Close of Nov 18, 2026
100.99 198.87
Market cap
USD 10.4B
P/E
-
P/B
4.97x
ROE
-1.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RGEN.US undervalued?

Graham number

The Graham number of Repligen Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Repligen Corporation fundamental analysis

No fundamental analysis for Repligen Corporation yet.

Repligen Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Repligen Corporation

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a …

Full company profile